ProQR (0PQ) Price & Analysis

3 Followers

0PQ Stock Chart & Stats

€1.62

€0.02(0.97%)

At close: Jan 08 4:00 PM EST

€1.62

€0.02(0.97%)

Day’s Range― - ―

52-Week Range€1.14 - €2.56

Previous CloseN/A

Volume0.00

Average Volume (3M)85.00

Market Cap

€204.99M

Enterprise Value€85.27M

Total Cash (Recent Filing)€81.17M

Total Debt (Recent Filing)€13.70M

Price to Earnings (P/E)―

Beta1.48

Next Earnings

Jul 30, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding132,986,860

10 Day Avg. Volume0

30 Day Avg. Volume85

Financial Highlights & Ratios

PEG Ratio-0.38

Price to Book (P/B)3.67

Price to Sales (P/S)11.85

P/FCF Ratio-3.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€7.60

Price Target Upside369.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.42

Revenue Forecast (FY)€11.78M

Bulls Say, Bears Say

Bulls Say

Platform Clinical ValidationClinical proof-of-concept for AX-0810 validates the Axiomer RNA-editing platform, materially de-risking the technology. This durability supports advancement of follow-on candidates, strengthens partner confidence, and underpins long-term pipeline value beyond a single trial readout.

Strategic AI And Discovery PartnershipAccess to Ginkgo's Nebula and AI advisory expertise creates a scalable discovery engine, increasing candidate throughput and hit quality. That structural capability can lower long-term R&D costs per program and provide a sustained competitive advantage in RNA drug discovery.

Bolstered Funding And Strategic Investor SupportThe recent equity raise plus Lilly's private placement strengthens the balance sheet and extends runway, reducing near-term financing risk. Lilly's participation is a strategic endorsement that can facilitate collaboration continuity and longer-term program funding.

Bears Say

Sustained Cash BurnPersistent negative OCF and FCF indicate the business is not self-funding and remains dependent on external capital. Over a multi-quarter horizon this structurally increases dilution and constrains investment flexibility if capital markets tighten or financing terms worsen.

Revenue Decline And Non-commercial ModelA declining revenue base and absence of commercial product sales mean ProQR lacks stable operating cash inflows. Reliance on milestone/collaboration payments leaves funding lumpy and increases project execution dependency on partners and successful trial outcomes.

Large Losses And Equity ErosionExtremely negative margins and falling shareholders' equity reflect ongoing erosion of financial resilience. Continued large losses can force more frequent dilutive financings, weaken negotiating leverage with partners, and limit strategic optionality over the medium term.

ProQR News

ProQR Therapeutics registers to sell 3.03M ordinary shares for holders

This filing relates to the offer and sale from time to time by the selling stockholders of up...

5d ago

PRQR

ProQR Therapeutics price target lowered to $10 from $14 at Raymond James

Raymond James lowered the firm’s price target on ProQR Therapeutics (PRQR) to $10 from $14 and keeps a...

15d ago

PRQR

ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch

JonesResearch analyst Catherine Novack lowered the firm’s price target on ProQR Therapeutics (PRQR) to $10 from $11 and...

15d ago

PRQR

ProQR Therapeutics price target lowered to $3 from $4 at Chardan

Chardan analyst Keay Nakae lowered the firm’s price target on ProQR Therapeutics (PRQR) to $3 from $4 and...

16d ago

PRQR

ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering

ProQR Therapeutics (PRQR) announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares at an...

16d ago

LLY

PRQR

ProQR Therapeutics announces positive Phase 1 data for AX-0810

ProQR Therapeutics (PRQR) announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the...

16d ago

PRQR

ASE, ProQR, AbSci, Ultragenyx, YPF: Insider Turmoil

Insiders have been trading these 5 stocks: (($ASX)), (($PRQR)), (($ABSI)), (($RARE)) and (($YPF)). Here is a breakdown of...

5h ago

ASX

YPF

ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement

ProQR ( ($PRQR) ) has shared an announcement. On June 25, 2026, ProQR Therapeutics priced an underwritten registered...

15d ago

PRQR

ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform

ProQR ( ($PRQR) ) has provided an announcement. On June 25, 2026, ProQR reported positive interim Phase 1...

16d ago

PRQR

ProQR Shareholders Approve Capital Increase, Board Changes at 2026 AGM

ProQR ( ($PRQR) ) has shared an update. On June 2, 2026, ProQR Therapeutics N.V. held its annual...

1M ago

PRQR

ProQR: Buy Rating Reiterated as Axiomer Pipeline Progress and Upcoming Catalysts Support Unchanged $12 Price Target

H.C. Wainwright analyst Ananda Ghosh has maintained their bullish stance on PRQR stock, giving a Buy rating yesterday....

2M ago

PRQR

ProQR Posts Q1 2026 Results as Axiomer RNA Editing Pipeline Advances

An announcement from ProQR ( ($PRQR) ) is now available. On May 12, 2026, ProQR reported first-quarter 2026...

2M ago

PRQR

ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position

ProQR ( ($PRQR) ) just unveiled an announcement. ProQR reported unaudited financial results for the three months ended...

2M ago

PRQR

ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders

ProQR ( ($PRQR) ) has issued an announcement. On May 4, 2026, ProQR Therapeutics announced that its Annual...

2M ago

PRQR

0PQ FAQ

What was ProQR Therapeutics BV’s price range in the past 12 months?

ProQR Therapeutics BV lowest stock price was €1.14 and its highest was €2.56 in the past 12 months.

What is ProQR Therapeutics BV’s market cap?

ProQR Therapeutics BV’s market cap is €204.99M.

When is ProQR Therapeutics BV’s upcoming earnings report date?

ProQR Therapeutics BV’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.

How were ProQR Therapeutics BV’s earnings last quarter?

ProQR Therapeutics BV released its earnings results on May 12, 2026. The company reported -€0.13 earnings per share for the quarter, missing the consensus estimate of -€0.12 by -€0.01.

Is ProQR Therapeutics BV overvalued?

According to Wall Street analysts ProQR Therapeutics BV’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ProQR Therapeutics BV pay dividends?

ProQR Therapeutics BV does not currently pay dividends.

What is ProQR Therapeutics BV’s EPS estimate?

ProQR Therapeutics BV’s EPS estimate is -0.11.

How many shares outstanding does ProQR Therapeutics BV have?

ProQR Therapeutics BV has 132,986,860 shares outstanding.

What happened to ProQR Therapeutics BV’s price movement after its last earnings report?

ProQR Therapeutics BV reported an EPS of -€0.13 in its last earnings report, missing expectations of -€0.12. Following the earnings report the stock price went up 2.601%.

Which hedge fund is a major shareholder of ProQR Therapeutics BV?

Currently, no hedge funds are holding shares in DE:0PQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ProQR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-86.47%

Trailing 12-Months

Asset Growth

-30.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ProQR Therapeutics BV

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

ProQR (0PQ) Earnings & Revenues

Historic Earnings Reports

0PQ Stock 12 Month Forecast

Average Price Target

€7.60

▲(369.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","11":"€11","2.75":"€2.75","5.5":"€5.5","8.25":"€8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.52111988,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.59858658,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.63027997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.601,2.287163067692308,2.9733261353846157,3.6594892030769235,4.345652270769231,5.03181533846154,5.717978406153847,6.404141473846155,7.090304541538463,7.77646760923077,8.462630676923078,9.148793744615386,9.834956812307695,{"y":10.52111988,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.601,2.0623528138461538,2.5237056276923076,2.9850584415384613,3.446411255384615,3.9077640692307694,4.369116883076924,4.8304696969230765,5.291822510769231,5.753175324615385,6.214528138461539,6.6758809523076925,7.137233766153846,{"y":7.59858658,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.601,1.6801753823076924,1.7593507646153845,1.838526146923077,1.9177015292307693,1.9968769115384615,2.076052293846154,2.1552276761538463,2.2344030584615386,2.3135784407692306,2.392753823076923,2.4719292053846154,2.5511045876923077,{"y":2.63027997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.683,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.792,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.874,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.763,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.276,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.694,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.303,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.265,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.373,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.296,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.342,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.601,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >